More than 10% increase in explanation before marketing
- Ardelyx, Inc. (Nasdaq: ARDX) share price rose more than 10% before market. That’s why it happened.
The share price Ardelyx, Inc. (Nasdaq: ARDX) – a biopharmaceutical company focused on the discovery, development and commercialization of innovative, first-class drugs to improve the treatment of people with kidney and cardio-renal disease – increased by more than 10% pre-market. Investors Respond to Company Announcement of PHREEDOM Company’s 52-Week Long-Term Phase 3 Trial in American Society of Nephrology Kidney360.
“The PHREEDOM trial, a 52-week randomized phase 3 trial that evaluated tenapanor as monotherapy, was the third of three phase 3 trials we conducted as part of our comprehensive evaluation of tenapanor for phosphorus control. serum in patients with chronic renal failure on dialysis. PHREEDOM data demonstrate the ability of tenapanor to provide significant phosphorus reduction with long-term safety comparable to active control. This study, along with data from our AMPLIFY trial which evaluated tenapanor in combination with binders in patients requiring more aggressive phosphate management, confirms the central role that tenapanor, with its novel blocking mechanism, may play in a wide range of patient and treatment regimens for the management of hyperphosphatemia in patients with chronic kidney disease on dialysis.
– Mike Raab, Chairman and CEO of Ardelyx
“As an investigator in this clinical trial and author of this publication, I have had the opportunity to see both directly and globally the impact of tenapanor on serum phosphorus control. I believe this new mechanism of therapy will play a key role in advancing the management of hyperphosphatemia in our CKD patients on dialysis, an area where treatment options are limited, and a significant proportion of patients have phosphorus levels above target ranges despite active treatment with currently available therapeutics. Additionally, a twice-daily one-tablet therapy that blocks phosphorus absorption, whether used alone or in combination with phosphate binders, has the potential to reduce the processing load, which will be a benefit. very significant benefit for patients.
– Arnold Silva, MD, Ph.D., director of clinical research at the Boise Kidney and Hypertension Institute
Disclaimer: This content is intended for informational purposes. Before you make an investment, you need to do your own analysis.